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Abstract
Background: The detection of Premature Stop Codons (PSCs) in human genes is very useful for
the genetic diagnosis of different hereditary cancers, e.g. Familial Breast Cancer and Hereditary
Non-Polyposis Colorectal Cancer (HNPCC). The products of these PSCs are truncated proteins,
detectable in vitro by the Protein Truncation Test and in vivo by using the living translation
machinery of yeast or bacteria. These living strategies are based on the construction of
recombinant plasmids where the human sequence of interest is inserted upstream of a reporter
gene. Although simple, these assays have their limitations. The yeast system requires extensive
work to enhance its specificity, and the bacterial systems yield many false results due to translation
re-initiation events occurring post PSCs. Our aim was to design a recombinant plasmid useful for
detecting PSCs in human genes and resistant to bacterial translation re-initiation interferences.
Results: A functional recombinant plasmid (pREAL) was designed based on a bacterial two-hybrid
system. In our design, the in vivo translation of fused fragments of the Bordetella pertussis adenylate
cyclase triggers the production of cAMP giving rise to a selectable bacterial phenotype. When a
gene of interest is inserted between the two fragments, any PSC inhibits the enzymatic activity of
the product, and translation re-initiation events post-PSC yield separated inactive fragments. We
demonstrated that the system can accurately detect PSCs in human genes by inserting mutated
fragments of the brca1 and msh2 gene. Western Blot assays revealed translation re-initiation events
in all the tested colonies, implying that a simpler plasmid would not be resistant to this source of
false negative results. The application of the system to a HNPCC family with a nonsense mutation
in the msh2 gene correctly diagnosed wild type homozygous and heterozygous patients.
Conclusion: The developed pREAL is applicable to the detection of PSCs in human genes related
to different diseases and is resistant to translation re-initiation events. The diagnosis steps are easy,
have a low cost, detect only pathologic mutations, and allow the analysis of separated alleles.
Background
The presence of Premature Stop Codons (PSCs) in tumor-
supressor and Mismatch Repair genes are a very frequent
cause of hereditary cancer that account for 50%-90% of
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the reported pathogenic mutations [1-3]. PSCs are
observed in the apc gene related to Familial Adenomatous
Polyposis (FAP) [4,5], the brca1 and 2 genes related to
Familial Breast Cancer [6-8] and the Mismatch Repair
genes related to Hereditary Non-Polyposis Colorectal
Cancer (HNPCC) [9,10]. PSCs are produced by nonsense
or frameshift mutations resulting in the premature termi-
nation of proteins [11,12]. These truncated proteins can
either loose completely their function producing haploin-
sufficiency in the cell or acquire a dominant negative
effect on the full-length protein produced by the wild type
allele [13,14]. In most cases, both consequences are path-
ologic. The mentioned genes related to hereditary cancers
show an extremely heterogeneous mutation spectrum,
but although the alterations are scattered throughout the
complete coding sequence, most of the identified muta-
tions produce premature termination of protein transla-
tion [15,16].
The detection of mutations in genomic DNA is one of the
most common diagnosis methods used for these diseases
– e.g. SSCP, DGGE, HA – [17,18]. These techniques have
the advantage of using only DNA -an easy to handle mol-
ecule- and have widely proved their usefulness. Still, they
have their limitations. They reveal all sequence changes,
including silent mutations and polymorphisms without
pinpointing the type of mutation. Therefore, subsequent
analyses are sometimes needed to distinguish between
pathologic mutations and polymorphisms [19].
The other major diagnosis methods are based on the
detection of the protein product, and they have the advan-
tage of detecting exclusively pathologic mutations. The
translation machinery is exquisitely sensitive to PSCs that
terminate the process of protein elongation. The analysis
of the truncated proteins can be done in vitro – e.g. Pro-
tein Truncation Test (PTT) – by starting from either
genomic DNA or RNA, amplifying the sequence to be ana-
lyzed, and using these products as templates for in vitro
transcription and translation [20,21]. The shorter prod-
ucts of the mutated alleles are then distinguished from the
full-length protein products of normal alleles. A disadvan-
tage of the conventional PTT is the involvement of SDS-
PAGE followed by autoradiography or Western blotting.
As it relies on visual inspection to detect the mobility of
shifted bands, it may also be subject to evaluator error.
Another limitation of the method is the lack of sensitivity
to diagnose mutations near the translation end that pro-
duce too small mobility shifts to be detected [20].
The PTT test is based on cell-free transcription and trans-
lation. However, the same machinery is present and func-
tional in living cells. Therefore, in principle, it would be
possible to carry out the diagnosis by using the translation
machinery of cells. Several models have been developed
in the past that use living-system strategies. For these
methods, PCR amplifications of consecutive fragments of
the gene are introduced in a reporter-plasmid, which is
then transformed into yeast or bacteria [22]. The DNA to
be tested is ligated upstream an easily detectable protein.
The presence of a PSC in the sequence will stop transla-
tion prematurely and prevent the expression of the
reporter protein.
The so called "yeast-based stop codon assay" has been
reported for the detection of chain-terminating mutations
in some specific genes. The PCR-amplified coding
sequence is inserted by homologous recombination into
a yeast expression vector system, and transformants are
assayed for growing in a nutrition-deficient medium. To
allow the insertion of the DNA sequence by homologous
recombination, a gap-vector must be previously generated
to introduce homologous flanking sequences for the pos-
terior recombination insertion step. Therefore, this
method requires the construction of an expression vector
that is specific for each tested sequence (e.g. exon), and
hence is not applicable to a new candidate gene. A modi-
fication made by Kataoka et al [23], consists of the devel-
opment of a universal gap-vector to permit the automatic
integration of any gene fragment. Each primer used to
amplify the sequence of interest carries a 24bp recombina-
tion tail. However, this method requires performing a
nested PCR to reduce nonspecific amplification products;
hence, it has many steps for a routine diagnosis.
Bacteria have the advantage of being easier to manipulate
than yeast. However, even though some authors have
reported the development of bacterial systems based on
the cloning of relevant segments in-frame with a colori-
metric marker gene [24], no data was found reporting
their application in routine diagnosis. A problem with
this strategy is the capability of bacteria to re-initiate trans-
lation downstream of the STOP, causing expression of the
reporter even in the presence of a PSC (false negative diag-
nosis) [25].
The aim of this work was to develop an alternative meth-
odology to detect PSCs in human genes using the tran-
scription and translation machinery of bacteria while
avoiding the translation re-initiation interference. The
strategy was to introduce the DNA to be tested in a linker
between the two fragments of the catalytic domain of ade-
nylate cyclase (cya) of Bordetella pertussis, used for the bac-
terial two-hybrid system developed by Karimova et al
[26]. Re-initiation events will render two separate cya
domains catalytically inactive. Our results show that the
plasmid is a sensitive, specific, efficient and low-cost tool
for the detection of PSCs and that it is insensitive to re-ini-
tiation artifacts.BMC Biotechnology 2006, 6:38 http://www.biomedcentral.com/1472-6750/6/38
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Results
Development of the recombinant pREAL plasmid
Our aim was to develop an alternative methodology to
detect PSCs in a human gene based on its fusion with a
reporter gene and on bacterial phenotype screening. Pre-
vious developments in this field produced false-negative
results, probably due to translation re-initiation events, so
we designed a recombinant plasmid in order to avoid this
artifact. The strategy was based on the bacterial two-
hybrid system developed by Karimova et al [26] to iden-
tify interacting proteins. In essence, when the catalytic
domain of Bordetella pertussis adenylate cyclase (encoded
by the cya gene) is expressed in E. coli, it exhibits a strong
unregulated basal activity that results in cAMP synthesis
which, in turn, can trigger the expression of lacZ-regulated
genes [27] (Figure 1Aa). Interestingly, the catalytic
domain is composed of two independent fragments (T25
and T18) that are not able to re-associate and interact (Fig-
ure 1Ab). However, when both fragments are genetically
fused to two proteins of interest, each on different plas-
mids, the interaction between the two proteins results in
functional complementation between the two adenylate
cyclase fragments leading to cAMP synthesis (Figure 1Ac).
Functional analysis of Bordetella pertussis adenylate cyclase
activity can be easily monitored in an E. coli strain defi-
cient in endogenous adenylate cylcase (cya-) on indicator
plates (e.g. LB-X-gal or MacConkey media).
We reasoned that if we constructed a unique plasmid con-
taining both complementary fragments of the reporter
enzyme linked by a subcloned human gene of interest, the
adenylate cyclase would be functional only in absence of
any PSC in the subcloned DNA fragment. In the absence
of PSC in the linker, the two domains would be synthe-
sized as a single polypeptide with adenylate cyclase activ-
ity (Figure 1Ba). A PSC in the DNA fragment would stop
translation and the second domain required for adenylate
cyclase activity would not be present. Any possible trans-
lation re-initiation event downstream the PSCs would
yield physically unattached fragments that should not be
able to re-associate, and hence would not result in a false
negative result (Figure 1Bb).
The two cya domains expressed as a single polypeptide are 
catalytically active
To test the hypothesis that the linked domains of the two-
hybrid system translated from a single plasmid would
have adenylate cyclase activity, we amplified fragment
T25 (N-terminal domain of cya) from plasmid pKT25 of
the bacterial two-hybrid system, and inserted it upstream
and in frame with fragment T18 (C-terminal domain of
cya) in plasmid pUT18 to obtain pREAL. Part of the exist-
ing MCS present in this plasmid was preserved to facilitate
the insertion of human gene fragments (Figure 2A). We
transformed an E. coli strain (BTH102), deficient in ade-
nylate cyclase, with pREAL and plated the transformants
on MacConkey medium. We used as control BTH102
transformed with pUT18. The results revealed that the
BTH102 transformed with the pREAL expressed adenylate
cyclase activity (100% of the colonies showed an unmis-
takable red phenotype after 20 h, Figure 2Ba). In contrast,
control plates, transformed with pUT18 that expressed
only the C-terminal domain of cya, showed 100% white
colonies (Figure 2Bb). This result confirmed the correct in-
frame insertion of T25 upstream T18 and the functional
catalytic activity of both domains attached by a short frag-
ment of 10 amino acids.
The system can accurately detect PSC in human DNA 
fragments
To test whether pREAL could be used to detect PSCs in
human genes, three different fragments of exon 11 of the
brca1 gene were amplified from a healthy donor. Reported
pathogenic stop mutations related to breast and ovarian
cancer were introduced by a mutagenic PCR strategy using
the wild type DNA as template [28]. A nonsense (NS) and
a frameshift (FS) mutation were generated introducing the
alterations with two different forward primers. A wild type
(WT) version was used as control. All forward primers had
BamHI site overhangs and the reverse primer had a 5'
EcoRI site to facilitate insertion in the MCS of pREAL. The
annealing site of the reverse primer was carefully selected
to include ATG and GTG codons post PSC and in-frame
with T18, in order to detect translation re-initiation
events.
After inserting the different PCR products in pREAL, the
BTH102 cells were transformed and plated on LB-X-gal
medium. As expected, all bacteria carrying the wild-type
insert showed a blue phenotype (Figure 3A) whereas the
bacteria carrying the inserts with PSC (frameshift product
or nonsense product) showed a white phenotype (Figure
3B and 3C). The experiments showed consistent results
either on MacConkey (data not shown) or on LB-Xgal
media, confirming that the insertion of a 377–383 bp
human sequence allows the functional interaction of frag-
ment T25 with fragment T18. The results also show that
any PSC in the DNA linker (by nonsense codon or
frameshift) inhibits the catalytic activity of adenylate
cyclase.
Most of the PSC mutations in tumor suppressor and mis-
match repair genes causing hereditary diseases are present
in a single allele. Therefore, any diagnosis system should
be able to detect these mutations in heterozygous
patients. To mimic a heterozygous PCR product, we
mixed in a 1:1 proportion pREAL/wildtype and pREAL/
nonsense and transformed the BTH102 with this mix.
When plated on MacConkey, the phenotypes showed an
equal proportion of white (9.6 colonies/cm2 = 49.7%)BMC Biotechnology 2006, 6:38 http://www.biomedcentral.com/1472-6750/6/38
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and red (9.75 colonies/cm2  = 50.3%) (Figure 4Aa),
whereas the control plates of BTH102 transformed with
pREAL/wildtype showed 100% red colonies (Figure 4Ab).
To confirm that the inserts of the white colonies had dif-
ferent sequences from those of the red colonies, we ampli-
fied DNA directly from the colonies (primers are
represented with gray arrows in Figure 4B) touching with
a single pipette tip a red and a white colony. The resulting
mixed PCR product was heat denatured, and allowed to
re-hybridize at low temperature. Finally, the mixed DNA
product was ran in a non-denaturing PAGE. We expected
the formation of homoduplexes (double-strand DNA
composed by two complementary strands) in case of a
Principles for the design of pREAL Figure 1
Principles for the design of pREAL. A: Principle of E.coli two-hybrid system based on functional complementation of ade-
nylate cyclase domains of Bordetella pertussis. The two spheres represent the T25 and T18 domains corresponding to amino 
acids 1–224 and 225–339 of the cya protein. In a, the full-length catalytic domain, when expressed in the cya- BTH102 strain 
exhibits a basal activity that results in cAMP synthesis. In b, the two independent fragments are unable to interact and no cAMP 
is synthesized. In c, the two fragments, fused to two interacting proteins -X and Y- are brought into close proximity, resulting 
in functional complementation followed by cAMP production. B: Principle of the design of the pREAL plasmid. Both adenylate 
cyclase fragments (T25 and T18) are subcloned into the same plasmid, leaving a multiple cloning site in between to insert a 
fragment of a human gene of interest. In a, T25 and T18 are linked by a human polypeptide chain and are functionally active 
when a PSC-free human gene is introduced in pREAL. In b, any PSC in the human gene inhibits the complete translation of both 
fragments as a single protein. In case of an in-frame translation re-initiation event post PSC, T18 will be present but unable to 
interact with T25; hence no cAMP will be synthesized.
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mix with identical sequences, and the detection of heter-
oduplexes (double-strand DNA composed by two not
completely complementary strands) in case of a mix with
different sequences. The heteroduplexes are easily detect-
able by their delayed mobility on an electrophoresis assay.
The PAGE showed the formation of heteroduplexes only
in the mixed product, confirming that it contained differ-
ent sequences (Figure 4C). In conclusion, these experi-
ments indicate that insertion of a PSC-containing DNA in
pREAL is easily detected by bacterial colony phenotype
and that the assay is suitable for analyzing heterozygous
samples.
PSCs were accurately detected even in the presence of re-
initiation events
We speculated that the developed diagnosis system would
be resistant to translation re-initiation, a common event
in bacteria. To detect whether translation re-initiation
events were occurring in our system, we used a murine
anti-adenylate cyclase monoclonal antibody that binds to
the distal portion – amino acids 373–399 – of fragment
T18 (C-terminus domain of the protein). Our hypothesis
was that, in the absence of PSC, a large product (59 kDa)
would be detected by the antibody, whereas in the pres-
ence of PSC, if translation re-initiations occurred, smaller
products recognized by the antibody should appear.
Western Blot assays were performed on extracts from
BTH102 transfected with empty pREAL, pREAL/WT,
pREAL/FS and pREAL/NS. The results in Figure 5 show
that small fragments recognized by the antibody were
present in all samples, indicating that translation initia-
tion downstream the stop codon was frequent and that it
occurred even in the DNA fragment lacking PSC. A careful
analysis of the sizes showed that they were consistent with
the ATG and GTG codons present in the linker. However,
it is worth noting that the full-length product was only
present in the adenylate cyclase positive (i.e., red colony)
bacteria. The results show that translation re-initiation is
a frequent event under the conditions of the assay and
that a reporter gene located downstream the inserted DNA
would not be a good method to detect PSCs. This obser-
Design and functional testing of pREAL Figure 2
Design and functional testing of pREAL. A: Design of pREAL with a MSC to insert human DNA fragments. B: Functional 
testing of pREAL. In a, the BTH102 transformants with empty pREAL were plated on MacConkey medium. All the colonies 
were red after 20 h at 37°C. In b, BTH102 transformants with pUT18 were plated on the same medium as control experiment. 
After 20 h at 37°C, all colonies were white.
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vation stresses the importance of the pREAL two-domain
strategy developed to detect stop codons in the inserted
DNA.
The system correctly detects a truncating mutation in a 
HNPCC patient
The pREAL plasmid has proved to be very efficient to
detect stop codons introduced in exon 11 of the brca1
gene of a wild type DNA, even in heterozygous samples.
We wanted to test the system with another gene and in a
more realistic situation. For this propose, exon 13 of the
msh2 gene was amplified from DNA obtained from
Detection of heterozygous condition Figure 4
Detection of heterozygous condition. A: a. BTH102 
were transformed with pREAL/WT:pREAL/NS in a 1:1 pro-
portion to test the detection system for heterozygous PCR 
product. Gray arrows show white colonies. b: BTH102 were 
transformed with pREAL/WT as homozygous control. B: 
localization of the primers (arrows in gray) used to amplify 
DNA fragments from red and white colonies to detect het-
eroduplex formation. C: DNA was amplified directly from 
colonies. Red and white colonies were touched with a 
pipette tip, added to the same PCR mix for amplification, 
afterwards heat denatured, and allowed to re-hybridize at 
low temperature. The obtained products were run on a non-
denaturing 8% PAGE. In lane 2, the appearance of two slowly 
migrating bands indicates the presence of heteroduplexes 
(black arrows) in the mixed sample (WT/NS product). Lanes 
1 and 3 are non-combined red and white colonies amplified 
in different PCR mix, used as controls. In these lanes, the 
heteroduplex bands are absent.
A
C
WT               Mix NS
Homo 
duplex
Hetero
duplex
b
ColEI
a
T18
bla (Amp R)
B
Ori
Primer
Forward
Primer
Reverse T25
bla (Amp R
pREAL
+
BRCA1
BRCA1
1                    2               3
Detection of inserts with PSCs through blue/white pheno- types in transformed BTH102 bacteria Figure 3
Detection of inserts with PSCs through blue/white 
phenotypes in transformed BTH102 bacteria. Three 
different fragments, Wild Type (WT), Nonsense (NS), and 
Frameshift (FS), were obtained by mutagenic PCR from exon 
11 of the human brca1 gene and inserted in pREAL. BTH102 
transformed with pREAL were plated on LB-Xgal medium. 
All plates are shown on white and black backgrounds. In A, 
BTH102 were transformed with pREAL/WT. Colonies show 
the blue phenotype consistent with an active adenylate 
cyclase and a PSC-free DNA insert. In B, BTH102 were 
transformed with pREAL/FS, and in C, BTH102 were trans-
formed with pREAL/NS. In the two latter cases, almost all 
colonies are white, indicating the absence of adenylate 
cyclase activity, and consistent with the presence of a PSC in 
the inserted DNA. In C we observed a few Lac+ colonies. A 
possible source of these false negative results is bacterial 
phenotype reversion due to endogenous mutations. Notice 
that this reversion rate does not disturb the diagnosis.
WT insert
FS insert
NS insert
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B
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peripheral blood of a patient from a HNPCC family. This
family presents a mutation (TGA>TAA) on codon 711 of
this gene. The PCR product was inserted in frame in the
MCS of pREAL. Note that the patient was heterozygous;
hence, the PCR product contained both, the mutated and
the wild type alleles. DNA of an unaffected member of the
HNPCC family was used as control.
In this instance, transformation of BTH102 was per-
formed directly with the ligation product avoiding a pre-
vious miniprep purification step in order to simplify the
method. To improve the amount of transformants, the
culture expansion time was increased to 3 h. After 20 h of
incubation on MacConkey at 37°C, the transformants
with the DNA from an unaffected individual showed 12.5
colonies/cm2; all of them with a red phenotype (data not
shown). In contrast, transformants from the heterozygous
patient showed 12.5 white colonies/cm2  (48.3%) and
13.4 red colonies/cm2 (51.7%) (Figure 6A). The results
clearly indicate that the method accurately identifies a
PSC-containing DNA segment even in the presence of a
non-mutated allele. To confirm the genotype of the differ-
ent colonies, a PCR from red and white colonies and sub-
sequent restriction enzyme incubation was performed.
The results shown in Figure 6B confirm the presence of the
wild type insert in red colonies (PCR product completely
cleaved by the restriction enzyme, Figure 6B, lane 2) and
the mutated allele in white colonies (PCR product not rec-
ognized and not cleaved by the restriction enzyme, Figure
6B, lane 4).
In the assay with the brca1 exon, the reverse primer was
designed in order to include ATG and GTG sequences on
purpose to test the robustness of the method to transla-
tion re-initiation problems. We assessed the occurrence of
re-initiation in this more realistic assay with the DNA
Detection of re-initiation events by Western Blot Figure 5
Detection of re-initiation events by Western Blot. BTH102 were transformed with empty pREAL, or pREAL ligated to 
the WildType, Nonsense or Frameshift fragments of the brca1 gene. Transformants were cultured, centrifuged, and the protein 
pellets were resolved on 10% SDS-PAGE. The membrane with the transferred proteins was probed with a monoclonal anti-
body for fragment T18. The corresponding insert sequences are shown at the right. PCR primer sequences are shown in gray, 
stop codons in red, and translation initiation codons in green. Lane1: BTH102 transformed with empty pREAL. A 45 kDa band 
is observed corresponding to the fused T25 and T18 fragments. Lane 2: BTH102 transformed with pREAL/WT (wild type exon 
11 of brca1). The upper band of 59kDa corresponds to the T25-insert-T18 protein. Two smaller fragments can be observed, 
likely produced by translation re-initiation events from two downstream and in-frame ATG codons. The lowest band (21 kDa) 
corresponds to translation re-initiation of fragment T18. Lane 3: BTH102 transformed with pREAL/FS (exon 11 of brca1 with a 
frame shift mutation that introduces a PSC). Notice the absence of the complete 59 kDa fragment due to the presence of a 
TAA stop codon. The presence of two smaller fragments can be explained by two in frame initiation codons (GTG and ATG). 
The lowest band corresponds to translation re-initiation of fragment T18. Lane 4: BTH102 transformed with pREAL/NS (exon 
11 of brca1 carrying a nonsense mutation). The absence of the full-length 59 kDa fragment is caused by the TAA codon 
included in the primer sequence. One smaller fragment is observed, consistent with an initiation ATG codon. Again, the lowest 
band corresponds to fragment T18.
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Application of the method to a HNPCC patient with a PSC Figure 6
Application of the method to a HNPCC patient with a PSC. A: BTH102 were transformed with pREAL carrying a 
msh2 insert obtained from a heterozygous patient. The proportion of red/white colonies was 51.7% and 48.3% respectively. B: 
Confirmation of the genotype of the different colonies by PCR and RFLP resolved on 10% non-denaturing PAGE. Lane 1 shows 
the 86bp PCR product of a red colony, without enzymatic incubation. Lane 2: PCR product obtained from a red colony, with 
subsequent enzymatic incubation. The 67 bp band results from the complete cleavage of the wild type allele in two smaller frag-
ments of 67 bp and 19 bp (band not shown). Lane 3: PCR product obtained from a white colony, without enzymatic incubation. 
Lane 4: PCR product obtained from a white colony, with subsequent enzymatic incubation. The 86bp band in the mutated allele 
is not recognized by HaeIII and is not cleaved. C: Western blot analysis of red and white colonies. In lanes 1 and 2, controls for 
fragment T18 and fragment T25-18 are shown. In lane 3, the western blot on the red colony reveals the presence of the com-
plete adenylate cyclase, with the wild type version of the msh2 fragment. Notice two re-initiation events: one that corresponds 
to fragment T18, and a larger band, that corresponds to the presence of an ATG codon in the insert. In lane 4, the Western 
blot of the white colony confirms the absence of full-lenght adenylate cyclase, and reveals the same re-initiation events seen in 
the red colonies, one corresponding to T18 and another corresponding to an ATG post PSC.BMC Biotechnology 2006, 6:38 http://www.biomedcentral.com/1472-6750/6/38
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amplified from a patient. Western Blot assays revealed the
presence of re-initiation events in red and white colonies
(Figure 6C, lanes 3 and 4), proving that a simpler plasmid,
based on the expression of a single reporter would have
strong limitations due to re-initiation events. Notice that,
as expected, white colonies do not express the full-length
(active) adenylate cyclase (Figure 6C, lane 4). These obser-
vations show that the pREAL strategy can be used in a rel-
atively simple diagnostic scheme: PCR amplification from
genomic DNA from patients, ligation into pREAL, trans-
formation with the ligation product into BTH102, and
bacterial phenotype screening in MacConkey or LB-Xgal
media.
Discussion
The diagnosis of hereditary diseases by molecular biology
methods has proved to be a powerful tool for the manag-
ing of affected families and, in many cases, for the treat-
ment of affected members. With a growing number of
genes identified as related to specific syndromes, these
methods are of great interest to the medical community.
Although feasible, the complete sequencing of the sus-
pected gene is still not efficient. Moreover, many muta-
tions may be normal polymorphisms without
pathological significance. Morbid mutations are fre-
quently related to inactivation of the gene product by the
conversion of wild type triplets to stop codons, or changes
in the reading frame that usually introduce stop codons.
Therefore, the detection of PSCs in disease-related genes is
usually of great importance for the diagnosis of hereditary
diseases.
We describe here a bacterial system that allows the detec-
tion of PSCs in human genes by a simple colony pheno-
type screening. The idea was originated in the two-hybrid
system based on a reconstituted signal transduction path-
way in bacteria, developed by Karimova et al [26] in the
Pasteur Institute. In our design, the in vivo translation of
Bordetella pertussis adenylate cyclase fragments linked by a
PSC-free inserted DNA triggers the expression of cAMP-
dependent genes. We took advantage of the fact that the
T25 and T18 fragments are unable to recognize each other
and cannot reconstitute a functional enzyme when
expressed as separate entities. However, if they are
attached by a polypeptide chain, the protein is active and
cAMP is synthesized. Ultimately, cAMP, upon binding to
CAP, activates the transcription of catabolic operons,
allowing the bacteria to ferment carbohydrates such as
maltose or lactose. We show here that any PSC in the DNA
inserted between the adenylate cyclase fragments inhibits
the activity of the translation product. We also show that
translation re-initiation events do occur and that the
pREAL system is resistant to this source of false negative
results. Indeed, re-initiation was a very common event
observed even in sequences lacking PSCs. We showed by
Western blot that most of the possible initiation codons
in the inserted fragment were used and generated a detect-
able polypeptide in the assay.
Patients with hereditary mutations in tumor suppressor
genes are always heterozygous, because homozygous indi-
viduals are unviable. Hence, a mixed PCR product is
obtained when DNA from these patients is amplified.
However, a single PCR product is inserted per copy of the
pREAL plasmid; in turn, only one pREAL copy transforms
a cya- bacterium that expands in a clone on the plate.
Therefore, each colony represents one allele. In conclu-
sion, this method allows the analysis of separated alleles
of heterozygous patients, avoiding possible allele-interfer-
ing events affecting other mutation detection systems
[29].
For the application of the pREAL plasmid, we propose a
diagnosis algorithm starting from genomic DNA extracted
from peripheral blood of index patients suspected of FAP,
HNPCC, Familial Breast Cancer, or any other disease
related to PSCs. Each exon should be amplified with spe-
cific primers carrying endonuclease cleavage sequences.
The amplification products should be subsequently
inserted into pREAL, and BTH102 cells transformed
directly with the ligation product. After plating on MacCo-
nkey for 20 hours, heterozygous exons with a PSC in one
allele would be detected by a 50/50 red/white phenotype.
To test the rest of the family members, only the affected
exon should be amplified and inserted into pREAL to
detect the presence or absence of the PSC.
The more complex step in this algorithm is the ligation of
the PCR product into pREAL because it involves incuba-
tion with restriction enzymes and purification of the
cleaved insert. Some strategies for directional in frame
ligation have been developed by commercial companies
(TOPO TA Cloning kits, Invitrogen Life Technologies). In
addition, mRNA could be used as template, allowing the
amplification by RT-PCR of consecutive exons and there-
fore reducing the cleavage/ligation steps. However, one of
the disadvantages of the RNA-based approaches is the
requirement for abundantly expressed and stable tran-
scripts. In particular, mRNAs carrying PSCs are degraded
by a specific mechanism (Nonsense Mediated Decay sys-
tem) that prevents the translation of truncated proteins
[30]. Hence, the amount of mRNA carrying PSCs is highly
reduced. Therefore, mRNA might not be a recommenda-
ble starting material for routine diagnosis.
Another predicted problem with the pREAL strategy is the
possibility that the three-dimensional structure of the
polypeptide chain linking the adenylate cyclase fragments
may interfere with the functional interaction between the
domains yielding an inactive enzyme. This false positiveBMC Biotechnology 2006, 6:38 http://www.biomedcentral.com/1472-6750/6/38
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result would be easily detected because white colonies
will be observed with control wild type inserts. If this
problem is detected for an exon of a gene, Western blot
analysis should be required to test the presence of full-
length protein in the colonies. Alternatively, a different
mutation detection system should be used for this exon.
All in all, adenylate cyclase activity was detected with the
three different linkers tested in the present report (i.e.,
empty vector, and pREAL carrying wildtype fragments of
exon 13 of the msh2 gene and exon 11 of the brca1 gene).
In conclusion, before using for clinical diagnosis, this
method should be tested for each exon of the gene of
interest in control and PTC containing samples. Moreo-
ver, the accuracy and efficiency of the system to detect
PTCs should be confirmed by future prospective studies.
Conclusion
The pREAL plasmid is applicable for the detection of PSCs
in human genes related to different diseases and is resist-
ant to translation re-initiation events. The diagnosis steps
are easy and have a low cost. They require only a labora-
tory equipped for DNA extraction, PCR amplification,
ligation, and bacterial culture. The most relevant biologi-
cal advantages of the method are the detection of only
pathologic mutations, thus avoiding subsequent analysis
for possible polymorphisms, and the analysis of separated
alleles in heterozygous patients.
For human genes with a high frequency of PSCs, this tool
can be applied as a first screening method in an exon by
exon strategy. In developing countries, where present
methods of molecular diagnoses of hereditary cancers are
still expensive and unaffordable for many families, this
mutation detection system may become a useful and
applicable tool.
Methods
Strains and growth media
DMH1 (F-, cya-854, recA1, endA1, gyrA96, thi1, hsdR17,
spoT1, rfbD1, glnV44), BTH101 (F-, cya-99, araD139,
galE15, galK16, rpsL1, hsdR2, mcrA1, mcrB1), and
BTH102 (F-, cya-99, recA1, sr1A::Tn10) are adenylate
cyclase deficient strains (cya-) and were used for the bacte-
rial phenotype screening setup. XL1-B strain (F-  lac,
proAB+  lacIq  lacZΔM15 Tn10 Tetr, cya+, recA1 endA1
gyrA96 thi-1 relA1hsdR17 supE44) was used to clone the
original plasmids of the two hybrid system and the recom-
binant plasmid pREAL. Frozen competent cells were
thawed and transformed using a CaCl2  protocol. The
growth medium used was rich Luria-Bertani (LB) supple-
mented when required with 100 μg/ml ampicillin or 50
μg/ml kanamycin. Screening for the ability to ferment lac-
tose was performed either on MacConkey agar plates
without additional maltose or on LB plates containing 40
mg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-galato-
pyranoside).
Development of the pREAL plasmid
Two plasmids from the bacterial two-hybrid system were
used: pKT25 (coding for the T25 fragment – aminoacids
1–224 – of the catalytic domain of adenylate cyclase) and
pUT18 (coding for the T18 fragment – aminoacids 225–
399 – of the catalytic domain of adenylate cyclase). To
generate pREAL, we inserted the T25 sequence in pUT18,
upstream and in frame with the T18 fragment. Cloning
attempts with pREAL in cya- strains (DMH1, BTH101)
were not successful and surprisingly the best cloning
results were obtained in XL1-B bacteria (cya+) that seemed
to resist the hypothetical excess of cAMP. The effect of
pREAL on bacterial phenotype was better observed in
BTH102, a rapid growing, cya-, endA, but also recA1
strain. Competent BTH102 (50 μl) were transformed with
2 μl of pREAL and after an expansion at 37°C for 45 min,
15 μl were plated on MacConkey medium with 100 μg/ml
ampicillin. Addition of 1% maltose or 0.1 mM IPTG to
the medium did not significantly improve the colony
number or growth rate.
Generation of human DNA fragments with PSCs by 
mutagenic PCR and insertion in the pREAL
Three versions of the exon 11 of the human brca1 gene
were generated with three different forward primers: i)
"nonsense product"(NS), with a TAA nonsense codon at
position 672 of the gene (5' GG GAT CCT TAA CCT GCA
ACT GGA), ii) "frame-shift product"(FS), with an inser-
tion of two base pairs, which provoked a frame shift and
a PSC at position 698, 25 codons downstream of the
insertion site (5' GG GAT CCA CTG CAA CTG GAG CCA
A), and iii) "wild type product"(WT) (5'GG GAT CCT
GCA ACT GGA GCC AA). Each of the forward primers was
combined with the same reverse primer (5' GGAATTC-
CTTGCCTTCCCTAGAG) to generate PCR products of
383, 379, and 377 bp, respectively. The annealing site for
the reverse primer was selected to include translation ini-
tiation codons (ATG and GTG) downstream of the PSCs.
The three different amplified products were cut with
EcoRI and BamHI (1 h at 37°C), purified from an agarose
gel, and inserted in the MCS of pREAL. After transforming
XL1-B, the plasmids were isolated using the Wizard Plus
Miniprep Purification system (Promega Corporation, Bio-
dynamics, Buenos Aires, Argentina). BTH102 were trans-
formed with pREAL/WT, pREAL/FS, pREAL/NS, and with
a 1:1 mix of pREAL/WT and pREAL/NS. After 45 minutes
of expansion, cultures were 1:3 diluted with LB and 15 μl
were plated on MacConkey medium. Without this dilu-
tion, we observed a few Lac+ colonies in BTH102/PSC
plates. A possible source of these false negative results is
bacterial phenotype reversion due to endogenous muta-
tions. The informed frequency of this events is 10-7 – 10-8BMC Biotechnology 2006, 6:38 http://www.biomedcentral.com/1472-6750/6/38
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[26]; however we observed a higher reversion rate (3–
6%), likely because of natural selection acting on the cya-
bacteria. Notice that this reversion percentage would not
disturb the diagnosis. Reverted colonies were seldom
found when the total number of bacteria per plate was
reduced by a 1:3 dilution with LB.
Heteroduplex analysis from red and white colonies
To confirm that the different colored colonies had differ-
ent inserts, white and red clones from the plate were
touched with a pipette tip. Both tips were added to a same
PCR mix to perform a single amplification from both col-
onies using the forward primer (5' GGTCCAAGCTT-
GGCTATGACCATGCAG) previously used to amplify
fragment T25, and the reverse primer used for brca1 exon
11. Then, the PCR products were boiled 5 min at 95°C
and renatured at RT for 30 min to allow the formation of
heteroduplexes. The samples were run on a non-denatur-
ing 8% PAGE for 3 h at 120 Volts. As control, separately
PCR products from white and red colonies were used. PCR
products were visualized by ethidium bromide staining
and UV light exposure of the gel.
Western blot of T18 to detect re-initiation events
50 μl of bacterial cultures were centrifuged at 10,000 rpm.
The bacterial pellets were resuspended in sample buffer
(10 μl), boiled for 5 min, and resolved on 10% SDS-PAGE
at 15mA. The gels were electroblotted onto nitrocellulose.
Membranes with transferred proteins were incubated with
murine anti-adenylate cyclase toxin monoclonal antibody
(3D1, List Biological Laboratories, INC, Campbell, Cali-
fornia, USA) (0.16 μg/ml) as primary antibody, followed
by incubation with anti-mouse IgG coupled to HRP
(Sigma-Aldrich, St Louis, MO, USA) (0.25 μg/ml) as sec-
ondary antibody. Chemiluminescence reaction using the
ECL kit (Amersham Bioscience, Buenos Aires, Argentina)
was carried out for 1 min followed by exposure to Kodak
XAR Radiograph film (Eastman Kodak, Rochester, NY,
USA) for 15 and 60 sec.
Application for the detection of a truncating mutation in a 
HNPCC patient
DNA of a previously diagnosed HNPCC patient [31], het-
erozygous for a PSC, was used as template. This patient
has a CGA>TGA nonsense mutation in codon 711 of gene
msh2. Primers were designed to include the PSC with 5'
overhangs for EcoRI and BamHI sites. The sequences of
the primers were: forward 5' AGGACTAAGGATCCATT-
TAT and reverse 5' TATGGAATTCCAAGCAGTTTCCAA-
CAT. A 277 bp PCR product was obtained, incubated with
EcoRI and BamHI for 1 h at 37°C, purified from an agar-
ose gel and inserted in the MCS of pREAL. To avoid the
subsequent miniprep purification step and carry out
directly the diagnosis screening, it was necessary to
increase the concentration of transformants before plat-
ing. Adding glucose during the expansion step and remov-
ing it before plating did not give a different number of
colonies on MacConkey or LB-Xgal. However, a three-fold
longer expansion time of the transformants before plating
produced enough colonies (80–100/plate) for a hetero-
zygous diagnosis. Hence, 50 μl of BTH102 were trans-
formed with 2 μl of recombinant plasmid, expanded in LB
in a shaker at 37°C for 3 hours. The culture was centri-
fuged and the pellet was plated on MacConkey medium
and incubated for 20 hours at 37°C.
To evaluate the different bacterial phenotypes on the plate
of the heterozygous patient, Western Blot assays were per-
formed as described on white and red colonies. To con-
firm the presence of the PSC in white colonies and its
absence in red colonies, a previously engineered PCR-
based diagnosis method was used [31]. The strategy is to
introduce a mutation that abuts the PSC site with the for-
ward primer. This mutation creates a restriction site for the
HaeIII enzyme only in the wild type allele, but not in the
allele carrying the PSC. Sequences of the diagnosis prim-
ers were: forward, 5'TTGTGGACTGCATCTTAGGC and
reverse, 5' CAGTTTCCAACATTTCAGCCA. White and red
colonies from the plate were touched with a pipette tip,
and each tip was separately added to a PCR mix with the
mentioned primers to run the amplification. PCR prod-
ucts were then incubated with the restriction enzyme
HaeIII for 1 h at 37°C, and run on non-denaturing 10%
PAGE.
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